Emedastine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Emedastine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
Line 1: Line 1:
{{drugbox
{{DrugProjectFormSinglePage
| IUPAC_name = 1-(2-ethoxyethyl)-2- (4-methyl-1,4-diazepan-1-yl)- benzoimidazole
|authorTag=<!--Overview-->
| image = Emedastine.png
|aOrAn=a
| CAS_number = 87233-61-2
|indicationType=treatment
| ATC_prefix = S01
|hasBlackBoxWarning=Yes
| ATC_suffix = GX06
|adverseReactions=<!--Black Box Warning-->
| PubChem = 3219
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| DrugBank = APRD00946
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
| C = 17 |H = 26 |N = 4 |O = 1
| molecular_weight = 302.415 [[Gram|g]]/[[Mole (unit)|mol]]
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| pregnancy_category =
| legal_status =
| routes_of_administration =
}}


'''Emedastine difumarate''' (Emadine&reg;) is an [[antihistamine]] used in [[eye drop]]s to treat [[allergic conjunctivitis]].
* Content


[[Category:H1 receptor antagonists]]
<!--Adult Indications and Dosage-->
[[Category:Antihistamines]]
[[Category:Benzimidazoles]]


{{Antihistamines}}
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====


{{pharma-stub}}
* Dosing Information
{{WikiDoc Help Menu}}
 
{{WikiDoc Sources}}
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Condition1
 
<!--Warnings-->
|warnings=* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Oral
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose====Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
 
<!--Structure-->
|structure=*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-

Revision as of 16:46, 23 February 2015

{{DrugProjectFormSinglePage |authorTag= |aOrAn=a |indicationType=treatment |hasBlackBoxWarning=Yes |adverseReactions= |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=ConditionName:

  • Content


|fdaLIADAdult======Condition1=====

  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage


|offLabelAdultGuideSupport======Condition1=====

  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Emedastine in adult patients.

|offLabelAdultNoGuideSupport======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Emedastine in adult patients.


|fdaLIADPed======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Emedastine in pediatric patients.


|offLabelPedGuideSupport======Condition1=====

  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Emedastine in pediatric patients.

|offLabelPedNoGuideSupport======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Emedastine in pediatric patients.

|contraindications=* Condition1

|warnings=* Description

Precautions

  • Description


|clinicalTrials=There is limited information regarding Clinical Trial Experience of Emedastine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

|postmarketing=There is limited information regarding Postmarketing Experience of Emedastine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

|drugInteractions=* Drug

  • Description

|useInPregnancyFDA=* Pregnancy Category |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Emedastine in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Emedastine during labor and delivery. |useInNursing=There is no FDA guidance on the use of Emedastine with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Emedastine with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Emedastine with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Emedastine with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Emedastine with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Emedastine in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Emedastine in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Emedastine in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Emedastine in patients who are immunocompromised.

|administration=* Oral

  • Intravenous

|monitoring=There is limited information regarding Monitoring of Emedastine in the drug label.

  • Description

|IVCompat=There is limited information regarding IV Compatibility of Emedastine in the drug label.

|overdose====Acute Overdose===

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Emedastine in the drug label.


|drugBox= |mechAction=*

|structure=*

File:Emedastine01.png
This image is provided by the National Library of Medicine.

|PD=There is limited information regarding Pharmacodynamics of Emedastine in the drug label.

|PK=There is limited information regarding Pharmacokinetics of Emedastine in the drug label.

|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Emedastine in the drug label.

|clinicalStudies=There is limited information regarding Clinical Studies of Emedastine in the drug label.

|howSupplied=* |packLabel= |fdaPatientInfo=There is limited information regarding Patient Counseling Information of Emedastine in the drug label.


Retrieved from "https://www.wikidoc.org/index.php?title=Emedastine&oldid=1072327"